{"filings":[{"id":513636,"accession_number":"0000019584-26-000014","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2026-05-19T14:43:59+00:00","items":["5.07"],"status":"ready","headline":"Chemed say-on-pay fails at annual meeting; 61% votes against","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-binding executive compensation proposal rejected: 4,383,683 For vs 6,926,656 Against (61.3% against).","All nine director nominees elected; Patrick P. Grace received 1,946,697 against votes (17.2%).","Ratification of PwC as independent auditor passed with 11,562,294 For (95.7% of votes cast).","Broker non-votes of 769,580 affected say-on-pay and director elections but not ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96926,"accession_number":"0000019584-26-000010","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q1 adjusted EPS $5.65; boosts 2026 guidance to $24.00-$24.75 on VITAS momentum","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $4.84, down 0.4% YoY; adjusted EPS $5.65, up 0.4% YoY.","Revenue $657.5M (+1.6%); VITAS revenue $420.0M (+3.1%); Roto-Rooter revenue $237.5M (-0.9%).","VITAS ADC up 2.2% to 22,723; admissions up 6.9%; adjusted EBITDA ex-Medicare Cap $70.8M (+0.6%), margin 16.8%.","Roto-Rooter adjusted EBITDA $53.5M (-9.6%), margin 22.5% (-218bps); acquired two franchises for $20.6M.","FY 2026 adjusted EPS guidance raised to $24.00-$24.75 from $23.25-$24.25; repurchased 500k shares for $197.7M in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":4.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":657513000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96925,"accession_number":"0000019584-26-000008","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["1.01","10.1","2.03","9.01"],"status":"ready","headline":"Chemed renews $450M senior secured credit facility for five years","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Five-year $450M revolving credit facility includes $100M letters of credit.","Interest rate is SOFR plus tiered spread based on Chemed's leverage ratio.","Facility includes an expansion feature allowing an additional $250M in capacity.","JPMorgan Chase is Administrative Agent; Bank of America, PNC, U.S. Bank also participating.","Credit Agreement dated April 10, 2026; press release issued April 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111296,"accession_number":"0000019584-26-000002","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q4 2025 GAAP EPS down 9%, Roto-Rooter segment weak; guidance for 2026 growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $639.3M flat YoY; GAAP diluted EPS $5.48 (-9%), adjusted EPS $6.42 (-6%).","VITAS revenue +1.9% to $418.8M, ADC +1.3% to 22,462, admissions +6%.","Roto-Rooter revenue -3.7% to $220.6M; adjusted EBITDA -21.1%, margin -477bps to 21.5%.","Repurchased 400,000 shares for $174.6M at avg $436.39; $127.3M remaining authorization.","FY2026 adjusted EPS guidance $23.25-$24.25 vs FY2025 $21.55; weighted to H2."],"consensus_eps_estimate":null,"consensus_eps_actual":18.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":2529978000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127903,"accession_number":"0000019584-25-000004","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q3 GAAP EPS falls 10.8% to $4.46; adjusted EPS down 6.6% to $5.27","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $624.9M (+3.1% YoY); VITAS revenue $407.7M (+4.2%), Roto-Rooter $217.2M (+1.1%).","VITAS ADC 22,327 (+2.5%); admissions up 5.6%; Medicare Cap accrual $6.1M vs $2.2M prior year.","Roto-Rooter adjusted EBITDA $49.4M (-12.4%); margin 22.7% vs 26.2% prior year.","Chemed: $129.8M cash, no debt; repurchased 407,500 shares for $180.8M during quarter.","Reiterates FY2025 adjusted EPS guidance $22.00-$22.30, assuming no Florida Medicare Cap."],"consensus_eps_estimate":null,"consensus_eps_actual":12.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":1890641000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144674,"accession_number":"0001562762-25-000181","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Chemed Q2 adjusted EPS $4.27 (-21.9% YoY); cuts FY2025 guidance; VITAS CEO departs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $3.57 (-23.2%); adjusted EPS $4.27 (-21.9%); revenue $618.8M (+3.8%).","VITAS adjusted EBITDA margin ex-Medicare cap 16.2% (-163 bps); Florida cap accrual $16.4M.","Roto-Rooter adjusted EBITDA margin 21.8% (-517 bps); revenue +0.6% to $222.6M.","FY2025 adjusted EPS guidance cut to $22.00-$22.30 from $24.95-$25.45; prior year $23.13.","VITAS CEO Nicholas Westfall resigns eff. July 29, 2025; Joel Wherley named successor."],"consensus_eps_estimate":null,"consensus_eps_actual":8.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1265741000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163076,"accession_number":"0001562762-25-000164","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Chemed projects $18-25M Medicare Cap hit; lowers FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VITAS expects $18M-$25M Medicare Cap revenue limit for Florida consolidated program (excl. Tallahassee) in 2025 Cap Year.","Lower-than-expected Medicare admissions in Apr-May 2025 and rate differential (2.9% cap increase vs 5.2% reimbursement) caused the cap.","Roto-Rooter experienced unexpected residential demand weakness in Q2 2025; commercial improvement insufficient to offset.","VITAS received Florida CON for Pinellas County on June 20, aiding growth and Cap mitigation for 2026.","Full Q2 2025 results and revised FY2025 guidance due July 29; conference call July 30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163075,"accession_number":"0001562762-25-000136","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Chemed shareholders elect all director nominees, approve 2025 stock plan and advisory compensation at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; Kevin McNamara received 12,805,746 for vs 203,421 against.","Shareholders approved 2025 Stock Incentive Plan with 11,536,322 for, 1,473,289 against.","Ratified PwC as independent auditor for FY2024 with 13,250,853 for, 365,426 against.","Non-binding advisory vote on executive compensation approved: 11,039,768 for, 1,656,237 against.","Shareholder proposal to reduce special meeting threshold to 10% not presented due to proponent absence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163074,"accession_number":"0001562762-25-000088","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q1 revenue up 9.8% to $646.9M; GAAP EPS $4.86, adjusted $5.63","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VITAS net revenue +15.1% to $407.4M; ADC 22,244 (+13.1%); adjusted EBITDA $70.3M (+15.9%).","Roto-Rooter revenue +1.8% to $239.5M but adjusted EBITDA -2.4% to $59.2M; margin down 108 bps.","Cash $173.9M; no debt; repurchased 50k shares for $29.8M at $595.15/share.","Covenant Health contributed ~$12M revenue, $2.6M EBITDA in Q1.","Full-year guidance update deferred to Q2 earnings release in June."],"consensus_eps_estimate":null,"consensus_eps_actual":4.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":646943000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180982,"accession_number":"0001562762-25-000032","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q4 2024 revenue up 9.2% to $640M; adj. EPS $6.83; guides FY2025 adj. EPS $24.95-$25.45","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $6.02 (+2.0% YoY); adjusted diluted EPS $6.83 (+3.5% YoY).","VITAS net patient revenue $411M (+17.4% YoY); ADC 22,179 (+14.6%).","Roto-Rooter revenue $229M (-2.9% YoY); adjusted EBITDA margin 26.3% (-120 bps).","FY2025 guidance: VITAS revenue growth 10.5%-11.3%, Roto-Rooter revenue growth 2.4%-3.0%.","No debt; $178.4M cash; repurchased 388,235 shares for $212.8M at $548.13/share."],"consensus_eps_estimate":null,"consensus_eps_actual":19.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":2431287000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197856,"accession_number":"0001562762-24-000241","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q3: rev $606M (+7.4%), adj EPS $5.64; FY2024 adj EPS guidance cut to $23.00-$23.15 on Roto-Rooter weakness","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $5.00 (+1.4%); adjusted diluted EPS $5.64 (+6.0%).","VITAS net patient revenue $391.4M (+17.3%), ADC 21,785 (+15.5%), adjusted EBITDA $73.1M (+33.1%).","Roto-Rooter revenue $214.8M (-6.9%), adjusted EBITDA $56.4M (-15.8%), margin 26.3% (-275 bps).","FY2024 adjusted EPS guidance revised to $23.00-$23.15 (targeting 13.3%-14.0% growth over 2023) due to softer Roto-Rooter results.","Repurchased 100,000 shares for $57.8M at $578.21/share; cash $238.5M, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":13.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":1791294000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214043,"accession_number":"0001562762-24-000179","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q2 adjusted EPS $5.47 (+34.1% YoY); raises FY2024 guidance to $23.55-$23.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $595.9M (+7.6%); GAAP EPS $4.65 (+32.5%); adjusted EPS $5.47 (+34.1%).","VITAS net patient revenue +16.7% to $374.6M; ADC +14.4% to 21,036; adjusted EBITDA +77% to $67.0M.","Roto-Rooter revenue -5% to $221.3M; adjusted EBITDA -9.2% to $59.8M; margin 27.0%.","FY2024 adjusted EPS guidance raised to $23.55-$23.80 (from $23.30-$23.70); VITAS EBITDA margin 19.3%-19.7%.","Repurchased 100k shares for $55.8M; cash $222.9M, no debt; $225.9M remaining buyback authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":8.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":1185113000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233266,"accession_number":"0001562762-24-000146","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Chemed annual meeting elects directors, approves PwC and say-on-pay, rejects termination pay proposal","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected; Kevin McNamara received 13.3M votes for, Patrick Grace 10.3M.","Ratification of PricewaterhouseCoopers as independent auditor for 2024 approved with 13.7M votes for.","Non-binding say-on-pay approved with 11.1M for vs 2.3M against (excluding 657,627 broker non-votes).","Stockholder proposal on termination pay ratification rejected with 1.0M for vs 12.4M against.","Meeting held May 20, 2024; all proposals received majority support except the stockholder proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233265,"accession_number":"0001562762-24-000096","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q1 2024: Adjusted EPS $5.20 beats; VITAS EBITDA surges 67%, Roto-Rooter down 16%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue +5.2% to $589.2M; GAAP EPS $4.24 (+18.4%); Adjusted EPS $5.20 (+21.5%)","VITAS net patient revenue +14% to $354M, ADC up 10.3% to 19,665; adjusted EBITDA +67.2% to $60.7M","Roto-Rooter revenue -5.8% to $235.2M, adjusted EBITDA -15.6% to $60.7M; margin down 299bps","Acquired Covenant Health hospice assets for $85M on Apr 17; no debt, $313.4M cash; bought back 50k shares for $32.3M","Full-year 2024 adjusted EPS guidance reaffirmed at $23.30-$23.70; next update with Q2 results"],"consensus_eps_estimate":null,"consensus_eps_actual":4.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":589233000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233264,"accession_number":"0001562762-24-000090","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"VITAS completes $85M acquisition of Covenant hospice operations in Florida and Alabama","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchased substantially all hospice operations and an assisted living facility from Covenant for $85M in cash.","Hospice markets include Pensacola, Tallahassee, Fort Walton Beach, Panama City in FL and Dothan, Mobile in AL.","Transaction was previously announced on March 13, 2024 and closed effective April 17, 2024.","Purchase funded using cash on-hand; no new debt or equity issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}